CTOs on the Move

B-One

www.b1.co

 
A few individuals with decades of experience in the U.S. orthopedic industry,came together in 2015 because they saw the need for a first-class company that was Agile,creative and innovative in a global market subject to advancing technologies and changing policies.They had seen the successes of the large companies, but they had witnessed compromises that had to be made.
  • Number of Employees: 0-25
  • Annual Revenue: $0-1 Million
  • www.b1.co
  • 636 Shelby Street 4th Floor
    Bristol, TN USA 37620
  • Phone: N/A

Executives

Name Title Contact Details

Funding

B-One raised $14M on 03/03/2020

Similar Companies

Advanced Microderm Inc

Advanced Microderm Inc is a Schaumburg, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Medtap International

Medtap International is a Bethesda, MD-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Obbligato Objectives

Obbligato Objectives is a Scarborough, ON-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Contego Medical

Contego Medical, founded in 2005, has developed a family of novel emboli protection devices. The main feature of each device is that the treatment portion (i.e., balloon or stent) is on the same catheter as the embolic protection device, thus coupling the two together. This device can act as an angioplasty balloon with an integrated emboli protection device. If a stent is mounted on the balloon, it can serve as a stent with an integrated emboli protection device. We know that embolization occurs with all angioplasty and stenting procedures. It is usually hard to predict which ones will result in clinical sequalae. Despite knowing that embolization is ubiquitous, embolic protection devices are not used in all procedures as they add complexity, time, and cost. Dedicated devices do not exist for renal intervention, although the majority of physicians say they would use one if it existed. Contego Medical’s family of embolic protection devices represent a paradigm shift in the treatment of cardiovascular disease.

PureFlora

PureFlora was founded in 2012 by Tivon Sidorsky, MD after a family member’s severe case of C. difficile introduced him to the efficacy of fecal matter transplants (FMT) and the need for a standardized, sanitary, and labor reducing system by which to collect, process, and deliver fecal matter. Recognizing the tremendous opportunity for research and clinical applications for human gut microbiota and the elegant solution proposed by Dr. Sidorsky, veteran medical device executive William L. Mince joined forces with the inventor building the now-patented technology and team that is PureFlora.